Covid news – live: EU withdraws controversial plan for vaccine export controls at Irish border
Follow for the latest developments
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The EU has backed down over its controversial plan to use a Brexit clause to stop Covid vaccines crossing the Irish border amid the ongoing row over jab supplies.
Downing Street had demanded an urgent explanation after the European Commission said it would trigger Article 16 of the Northern Ireland Protocol to ensure all citizens of the bloc have access to jabs and maintain transparency.
However the move was widely condemned across the UK and Ireland - with both Sinn Fein and the Democratic Unionist Party describing the move as “totally ill judged” and '"an incredible act of hostility".
The Commission later confirmed that it would not trigger Article 16 but warned that it would consider taking action if attempts were made to circumvent export controls imposed on vaccines produced within the bloc. The dispute began after AstraZeneca announced it would reduce its initial supplies of vaccines to the EU by 60 per cent.
It came as the European Medicines Agency granted authorisation for the AstraZeneca coronavirus vaccine for use in adults throughout the EU on Friday.
Meanwhile, a fourth Covid-19 vaccine could be approved for use in the UK in a matter of weeks after clinical trials showed the Novavax candidate was 89 per cent effective in preventing coronavirus.
The Novavax jab, which will be produced on Teesside, will now be assessed by the Medicines and Healthcare products Regulatory Agency (MHRA). The UK has secured 60 million doses of the vaccine, which is believed to offer protection against emerging variants, such as the new UK and South African strains.
- Tony Blair calls for world to come together to fight Covid
- EU steps up threat to block vaccine exports to UK by exploring ‘all legal means’ to keep supplies
- Dubai joins ‘red list’ with travel ban from UAE
- Does the new coronavirus strain have the same symptoms as the first?
- The vaccine bust-up between Britain and the EU is a lose-lose situation - but is it a sign of things to come?
Novavax vaccine 89% effective in preventing Covid, preliminary analysis finds
A coronavirus vaccine developed by US company Novavax is 89.3 per cent effective in preventing Covid-19 and nearly as effective in protecting against the new UK variant, according to late-stage clinical trials.
The vaccine will now be assessed by the Medicines and Healthcare products Regulatory Agency (MHRA), prime minister Boris Johnson has confirmed, and could become the fourth vaccine to be approved for use in the UK within weeks.
Find out more about the latest vaccine candidate from my colleague Conrad Duncan:
Novavax vaccine 89% effective in preventing Covid, preliminary analysis finds
PM says UK has ordered 60 million doses of jab which will be made in Teesside
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments